Replies to post #470202 on NorthWest Biotherapeutics Inc (NWBO)

[DavidW2]

Agree 100%!. This management team, OMG!

[OPennyS]

Yep, we were told to wait to avoid this very situation and ultimately they failed in their promised avoidance.

[ATLnsider]

I am going to withhold judgement until I learn more about the facts regarding why it was done this way.

But I think it was intended to give Dr. Liau an opportunity to announce the trial success, and to do it in front of her peers and colleagues worldwide. Unfortunately, she became ill and was unable to make the presentation herself. But, the trial data and results remain the same. The bears, shorts and MMs exploited Dr. Liau's illness, and took advantaged of fearful and anxious retail investors.

Unfortunately, a lot of retail investors do not understand or appreciate the trial results. Also, some retail investors are falling victim to bear arguments, like: the trial failed on PFS, the endpoints changes were done post hoc, etc. There were a lot of panic selling today, and tens of millions in Stop Losses were triggered.

[Troymister]

Exactly right.

[skitahoe]

I may be mistaken, but I don't believe the Journal prevents NWBO from issuing TLD, I believe it's a decision made by the company and today's presentation pretty much defines what they ought to be saying.

While I still do not understand why more than 50 people do not appear to be alive based on the K-M plots, and I believe that contradicts what Drs. Liau and Ashkan have said when discussing the Top 100, it's clear that there is a tremendous survival benefit long term.

In most trials that I've been aware of approval could be achieved with a 10 to 20% improvement on the SOC. Overall survival is the gold standard for judging outcomes and we're more than doubling the long term survival. I believe we'll get more information in the Journal, but while a TLD statement may need to say secondary end points weren't achieved due to pseudoprogression being taken as progression, the OS data is clearly a marked improvement and certainly worthy of approval without additional testing being required.

Gary